ArticleScientific reports2025
Efficacy of azathioprine in reducing recurrence in idiopathic granulomatous mastitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Utility of intercostal artery perforator flap in granulomatous lobular mastitis: a single-center retrospective study.Gland surgery · 2026Article
- Trimethoprim-Sulfamethoxazole in the Treatment of Idiopathic Granulomatous Mastitis: A Retrospective Cohort Study.Health science reports · 2026Article
- Article
- Personalized Treatment Outcomes in Idiopathic Granulomatous Mastitis: A Retrospective Study of Ninety-Two Patients.European journal of breast health · 2026Article
- Granulomatous Mastitis Mimicking Infection: A Case Report of Therapeutic Challenges and Evolving Management.Cureus · 2026Article
- Pittsburgh Classification and Treatment Algorithm for Idiopathic Granulomatous Mastitis: A Multicenter Cohort Study.European journal of breast health · 2026Article
- Idiopathic granulomatous mastitis: A narrative review based on the Turkish consensus classification.Turkish journal of surgery · 2026Article
- Molecular Targeted Therapy for Chronic Non-Bacterial Mastitis: New Insights into Pathophysiology and Therapeutic Strategies.International journal of women's health · 2026Review
- Methotrexate plus low-dose prednisolone compared with high-dose corticosteroid therapy in the management of idiopathic granulomatous mastitis.Archives of gynecology and obstetrics · 2025Article
- Variability in Clinical Response to Steroids in Granulomatous Mastitis: A Report of Two Cases.Cureus · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic granulomatous mastitis (IGM) is an immune-mediated inflammatory breast disease presenting significant treatment challenges due to its varied symptoms and lack of standardized guidelines. This study aims to evaluate the efficacy and safety of immunosuppressive modalities, including corticosteroids (CS) and immunosuppressive agents such as methotrexate (MTX) and azathioprine (AZA), in managing IGM, with a focus on recurrence rates and treatment outcomes. We conducted a retrospective analysis of 505 female patients diagnosed with IGM at the Bursa Uludag University Breast Surgery Clinic between January 2011 and December 2022. Patients received various treatments, including observation, CS therapy, MTX, AZA, and surgical interventions when necessary. Recurrence rates among different therapy groups were compared using chi-square tests, with Bonferroni correction applied for multiple comparisons. Of the total patients, 29.7% received first-line conservative therapy, while 70.3% required second or third-line immunosuppressive treatments. Among those who received immunosuppressive therapy (n = 355), CS therapy alone had the highest recurrence rate at 28.8%. The addition of MTX reduced the recurrence rate to 19.8%, but this reduction was not statistically significant (p = 0.143). AZA therapy significantly lowered recurrence rates, both when used alone (4.7%) and in combination with CS (9.1%) (p < 0.005). Patients treated with a combination of MTX and AZA had a recurrence rate of 4.8%. Overall, there were significant differences in recurrence rates among the therapy groups (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.